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Abstract
Background: Atrial fibrillation (AF) is the most common form of cardiac arrhythmia.
A number of studies have demonstrated that heart rate control is the first line therapy for
patients with AF. However, the correct ventricular rate and the parameters to be assessed are
still open to question. The aim of the study was to evaluate whether mean heart rate (mHR) in
24-hour ECG Holter monitoring (HM) is useful parameter for the assessment of ventricular
rhythm control in patients with AF. Additionally, we investigated whether other parameters
such as episodes of tachy AF, irregularity of rhythm and the patient’s awareness of “palpita-
tions” play an important role in controlling ventricular rate in AF.
Methods: Patients with chronic brady-tachy AF who had undergone VVI pacemaker implan-
tation between 2 and 9 days earlier (a mean of 5.6 days previously) with optimal pharmaco-
therapy and mHR below 90 bpm were enrolled in this study. The studied parameters included
mHR and the coefficient of irregularity (CI), based on HM and the percentage of fast ventricular
rates (tachy AF episodes defined as a heart rate of > 120 bpm) derived from the pacemaker memory
data. Symptoms such as “palpitations” were marked with a “+” over a period of 24 hours.
Results: Forty two patients (18 male, 24 female) with a mean age of 70.2 ± 8 years were
included in the study. Their mHR in HM ranged from 48 bpm to 79 bpm, with a mean of 64.8 ±
± 7.5 bpm. Despite of a correct mHR, in 21 patients (50%) tachy AF episodes were observed.
accounting for 1% to 8% beats, with a mean of 2.7 ± 2.02%. CI in HM varied from 0.9 to 0.33
with a mean of 0.23 ± 0.06. Significant irregularity, a CI above 0.2, together with a correct
mHR was found in 73% patients. In the majority of patients with a low CI of  < 0.2 (10 out of
11) there were no tachy AF episodes. A significant CI (> 0.2) was found in 10 out of
18 patients (56%) with a correct mHR and without tachy AF episodes. Palpitations were noted
in 16 out of 21 patients with the correct mHR who had tachy AF episodes and 9 out of 10, also
with the correct mHR, in whom no such episodes were recorded. All these patients had
a significant ventricular rate irregularity with a CI of > 0.2.
Conclusions: The parameter of mHR derived from HM is not sufficient for controlling
ventricular rate in the majority of patients with brady-tachy AF. It seems that evaluating tachy
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AF episodes, rhythm irregularity and symptoms experienced by the patient are also necessary
for establishing for correct control of the heart rate in patients with AF. The CI could be
superior to other parameters for the assessment of patients with AF who have correct mean
heart rate. (Folia Cardiol. 2006; 13: 473–479)
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Introduction
Atrial fibrillation (AF) is the most common form
of cardiac arrhythmia [1]. A number of studies have
demonstrated that heart rate control is the first line
therapy for patients with AF [2]. Analysis of ran-
domised trials have revealed no benefit either in
modality, morbidity or stroke prevention in rhythm
over rate control in AF patients [3–7]. According
to ACC/AHA/ESC guidlines, one-day mean heart rate
(mHR) in 24-hour ECG Holter monitoring (24 HM)
is currently considered as an established parame-
ter for ventricular rate control in AF patients [8]. It
would seem that mHR is the optimal endpoint for
the treatment of patients with AF [9]. Another es-
tablished criterion for ventricular rate control is to
maintain a rate of 60–80 bpm at rest and 90–115 bpm
during exercise [10, 11]. Correct ventricular rate
control is of such importance because a long-lasting
fast or irregular rate can lead to tachycardia-induced
cardiomyopathy [12, 13]. Unfortunately, tachy AF
episodes and significant irregularity may sometimes
occur in patients with a correct mHR. The correct
ventricular rate and the parameters that should be
assessed to optimize rate control is still debatable.
The aim of the study was to evaluate whether
mHR in 24 HM is the correct parameter for the
assessment of ventricular rate control in patients
with AF. Additionally, we investigated whether oth-
er parameters, such as episodes of tachy AF,
rhythm irregularity and patient awareness of “pal-
pitations”, play an important role in controlling ven-
tricular rate in AF.
Methods
A total of 48 patients were enrolled in the
study, each of whom had been implanted with a sin-
gle-chamber ventricular pacemaker (Biotronik,
Actros SR) in the Department of Cardiology of the
Medical University of Łódź. The indications for
pacemaker implantation were documented episodes
of heart-rate pauses of over 3 s in HM with com-
plete or incomplete Morgagni–Adams–Stokes syn-
drome. The correct ventricular rate defined by
24 HM in patients with optimal pharmacological
treatment was a mHR below 90 bpm in readings
taken between 2 and 9 days (at a mean of 5.6 days)
following implantation.
The diagnostic memory data collection function
of the Biotronik pacemakers was begun simultane-
ously with the start of traditional HM. Ventricular
sense events (Vs) and ventricular paced events (Vp)
were evaluated by means of an event counter. The
pacemaker was reprogrammed to the VVI mode of
40 bpm for the intrinsic ventricular rate in AF re-
cording.
The criteria for the enrolment of patients for
the final analysis were as follows:
— mHR according to ACC/AHA/NASPE Guide-
lines below 90 bpm [10];
— a percentage of paced events during 24 HM be-
low 5%.
24-hour Holter recordings
Ambulatory ECG Holter recordings were tak-
en by means of analogue Oxford MR 45-4 record-
ers with a pacemaker option and typical CS2, CM5
and IS leads; the recordings were analysed using
the Oxford Medilog Excel 2 system according to
ACC/AHA Guidelines [14]. Both automatic and
manual analyses were performed. After the record-
ings had been edited and visually verified, the fol-
lowing parameters were assessed: the percentage
of native rhythm beats (Vs), percentage of paced
beats (Vp), mean heart rate (mHR) and maximum
heart rate. Manual verification of ECG data also
included analysis of fusion and pseudofusion beats.
Fusion beats were determined when spikes did not
change the T-wave morphology in QRS complex-
es. The event counter classified fusion beats as
ventricular paced events (Vp) and the mean heart
rate was evaluated by means of 24 HM. The coeffi-
cient of irregularity (CI), defined as standard devi-
ation/mHR, was assessed in every patient. Accord-
ing to Greenhut’s et al. [15] study, irregularity of
the ventricular rate in AF was established as sig-
nificant when there was a CI > 0.2.
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Pacemaker memory data
As mentioned, the diagnostic memory data
collection of the Biotronik pacemakers was begun
simultaneously with the start of traditional HM.
From the different Actros S diagnostic memory
functions the following data were taken into analysis:
— from the event counter: the percentage of ven-
tricular paced events (Vp);
— from the activity report: the mean of the ven-
tricular rate (mHR);
— from the heart-rate histogram: percentages of
ventricular rates (Vs and Vp) within certain
heart-rate ranges. All results were retrieved
from the memory data during telemetry using
the Biotronik PMS 1000 programmer. 24 HM
and pacemaker memory data were terminated
at the same time. Episodes of tachy AF were
defined when ventricular rate was > 120/min.
Percentage of beats with rate > 120/min among
all recorded beats during 24 hour recording was
considered as a measure of tachy AF intensity.
Patients’ clinical symptoms
(heart palpitation)
Every symptom of a fast or irregular ventricu-
lar rate, such as heart palpitations, during 24 HM
was noted by patients with in a patient’s diary.
Statistical analysis
All data were calculated as mean values with
standard deviation.
Results
The final analysis included 42 patients (18 male
and 24 female), with a mean age of 70.2 ± 8 years. Six
patients with a mHR > 80 bpm were excluded from
the study. Clinical data and medication for 42 patients
with AF and a VVI pacemaker are shown in Table 1.
The majority of the patients, 32 (76%), were
classified as within NYHA classes I or II of heart
failure. Six patients were in NYHA class III, while
in 4 patients heart failure symptoms were not re-
ported. The left ventricle ejection fraction in ECHO
examination ranged from 22% to 81%, with a mean
of 60.9%. Coronary artery disease was present in
10 patients and 8 of these had myocardial infarction.
Mean 24 hour heart rate
The mHR during 24 HM ranged from 48 bpm
to 79 bpm, with a mean of 64.8 ± 7.5 bpm. The mHR
in 42 patients is shown in Figure 1.
Tachy AF episodes
In 21 patients (50%) with mHR within approved
ranges,  data retrieved from the pacemaker memo-
ry recorded tachy AF episodes (tachy AF) ranging
from 1% to 8% of beats, with a mean of 2.7 ± 2.0%.
The maximal heart rate was 202 bpm. Remaining
21 patients did not have tachy AF episodes. The
percentage of tachy AF episodes in all 42 patients
during 24 HM is shown in Figure 2.
Coefficient of irregularity
In the patients studied CI was between 0.9 and
0.33, with a mean of 0.23 ± 0.06. CI values in 42 pa-
tients with AF are shown in Figure 3. Significant
irregularity, defined as CI > 0.2, was observed in
Table 1. Clinical data and cardiovascular medica-
tions in 42 patients with atrial fibrillation and im-
planted pacemaker.
Hypertension 17
Valvular heart disease 2
Non-ischaemic cardiomyopathy 2
Coronary artery disease 10
Cardiac glycosides 25
Beta-blockers 37
Calcium channel blockers 10
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Figure 1. The mean heart rate (mHR) in 42 patients
recorded in 24-hour ECG Holter monitoring (24 HM).
    Value of mHR in studied patients during 24 HM.
Figure 2. Percentage of tachy AF episodes in 42 pa-
tients with correct mean heart rate in daily pacemaker
memory data.    Patients with tachy AF;   Patients wi-
thout tachy AF.
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73% patients with acceptable mHR. In 63% of these
patients, tachy AF episodes were recorded in
24-hour pacemaker memory data. In contrast, in
10 out of 11 patients with a low CI (< 0.2), no tachy AF
episodes were noted. It is also of interest that of
11 patients with CI < 0.2 tachy episodes were only
recorded in one.
The results in Figure 4 show that a correct
mHR and absence of tachy AF episodes are not
sufficient to claim that ventricular rate in patients
with AF is acceptable. Significant ventricular rate
irregularity (CI > 0.2) was found in 10 out of
18 patients (56%) with a correct mHR and without
tachy AF episodes.
Analysis of patient symptoms
(heart palpitation)
In 36 patients (85%), heart palpitations were
reported during 24 HM. Symptomatic palpitations
were found in 16 of 21 patients with tachy AF epi-
sodes. Other patients, although they had tachy AF
episodes recorded, they did not report any symp-
toms. It is important to underline, that 9 out of
10 patients without tachy AF episodes and with a cor-
rect mHR reported palpitations and that in all of these
CI was significantly high (CI > 0.2).
Discussion
The control of ventricular rate is an essential
aspect of the management of permanent AF. Pa-
tients with AF have been the subjects of intense
investigation over the past two decades (PAF,
RACE, AFFIRM, HOT CAFE). Two management
strategies have emerged over the years: rhythm
control, using anti-arrhythmic drugs and electrical
cardioversion to maintain sinus rhythm, and rate
control, designed to reduce symptoms by control-
ling an unusually rapid and irregular ventricular
response to AF. Reports have recently been pub-
lished of randomised trials which have found that
these two strategies are equivalent when measured
by a variety of endpoints [3–7].
If achieving rate control is made the goal, it is
essential to define this term adequately. Unfortu-
nately, evidence-based data to guide the clinician
are in short supply, and many published definitions
of rate control are somewhat arbitrary. Among many
parameters used to control ventricular rate, mHR
obtained from 24 HM is an accepted approach [9].
It is important to mention that according to ACC/
/AHA/ESC guidelines the ventricular rate in AF
patients should be evaluated at rest and with exer-
cise test. The patients in our study were elderly,
with a mean age of over 70, and it was decided not
to perform the exercise test. Additionally, accord-
ing to Kowey et al. [2], monitoring of the mHR in
24 HM seems to be the gold standard in the com-
plete assessment of patients with AF, allowing the
heart rate trend to be assessed over 24 hours dur-
ing daily activity. Appropriate rhythm control is
important since a fast ventricular rate > 120/min
might lead to tachycardiomyopathy [16]. Tachycar-
dia-induced cardiomyopathy is defined as a condition
characterised by ventricular myocardial dysfunction
resulting solely from an increased ventricular rate [17].
Gossage et al. [18] first described tachycardia-in-
duced cardiomyopathy in 1913 in patients with atrial
fibrillation. In the following years many studies
were published which showed that a prolonged un-
controlled fast ventricular rate can lead to tachycar-
diomyopathy [19–22]. The ventricular rate is there-
fore a major determinant of the onset and progres-
sion of tachycardia-induced cardiomyopathy and
may result in an altered geometry and function of
the ventricle, an increase in left ventricular area,
mitral regurgitation, elevated left ventricular end-
diastolic pressure and decreased left ventricular
wall thickness and ejection fraction [23]. These
abnormalities in left ventricular function result from
disturbances in the structure and biochemical
Figure 4. Coefficient of irregularity (CI) in 18 patients
with correct mean heart rate (mHR) and without tachy
AF episodes during 24-hour ECG Holter monitoring.
   Patients with correct mHR and without tachy AF.
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Figure 3. Coefficient of irregularity (CI) in 42 patients
with atrial fibrillation (AF) during 24-hour ECG Holter
monitoring.   Patients with AF and significant ventricular
rate irregularity (CI > 0.2).   Patients with AF and witho-
ut significant ventricular rate irregularity (CI £ 0.2).
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processes of the myocytes [9]. Proper control of
ventricular rate in patients with tachycardiomyop-
athy leads to faster improvement in left ventricu-
lar function than regression of pathology of myo-
cytes. However, reversal may not occur or may not
be complete in all cases [24, 25].
All these data suggest the importance of ven-
tricular rate control for preventing tachycardiomy-
opathy. The mean heart rate is determined by the
number of fast and slow ventricular rates. Where
the proportions of fast and slow rhythms are simi-
lar, mHR may be read as correct, and this may re-
sult in a false assessment of heart rate control.
In the majority of the patients in our study, the
tachy AF episodes were symptomatic, 76% of pa-
tients claiming “heart palpitation”. Such a significant
percentage of patients with tachy AF and symptoms
implies that clinical assessment of AF patients on the
basis of mHR only must be approached with caution.
The number of tachy AF episodes was calcu-
lated from the heart-rate histogram retrieved from
pacemaker memory data. Previous studies have
demonstrated that there is a very high correlation
between pacemaker and 24 HM data [26]. The ana-
lysis of tachy AF episodes could be done using Hol-
ter monitoring, however, such approach is very
time-consuming. The automatic function in pace-
makers facilitates this process.
Ventricular rate irregularity is an independent
factor which can lead to tachycardia-induced cardi-
omyopathy [27–29]. Sometimes it is impossible to
determine whether it is a fast or an irregular rate
that causes tachycardiomyopathy [30, 31]. Our
strategy for the management of ventricular rate
should be aimed at these two factors.
The first experimental study by Naito showed
that in dogs after complete atrioventricular nodal
ablation cardiac output significantly increased when
irregular pacing (150/min) was maintained [30].
Daoud et al. [31] reported data on 11 patients who
underwent atrioventricular ablation and who were
paced 80/min and 120/min on average with diferent
modes of regularity. During irregular rhythm, cardiac
output decreased by 12%. The studies in patients that
followed confirmed these results [32–38]. There are
few theories trying to elucidate causes of the de-
tremental effects of irregulatr heart rate on hemody-
namic parameters even in AF patients with accepta-
ble range of heart rate. First, stroke volume of left
ventricle in a cycle after a long pause is not able to
fully compensate decreased stroke volume after short
RR interval [35]. Secondly, level of atrial natriuretic
factor is higher during irregular rhythm because pres-
sure in the atria is changeable with tendency to
increase with longer duration of atrial fibrillation [36].
Thirdly, sudden changes in cycle length compromise
contractility of the myocardium [37].  Therefore, the
assessment of irregularity of heart rate in patients
with atrial fibrillation is of major importance.
The coefficient of irregularity, a quotient of
standard deviation and mHR (SD/HR), is an estab-
lished ventricular irregularity parameter [15]. It
could be calculated from HM and it has been used
in some clinical studies of patients with AF [15, 38].
In our study significant irregularity with a CI
of > 0.2 was found with a correct mHR in 76% of
patients. It may be concluded that in more than half
the patients with heart-rate control based only on
mHR there is a risk of tachycardiomyopathy devel-
oping. Additionally, in 56% of patients with a cor-
rect mHR and without tachy AF episodes a CI of
> 0.2 was noted. It may be that CI is more impor-
tant as a parameter for controlling ventricular rate
in AF than the mHR of tachy AF episodes. Control
of mHR alone may be insufficient to prevent tachy-
cardiomyopathy in the treatment of patients with
permanent AF. On the other hand tachy AF epi-
sodes were only found in 1 out of 11 patients with
a low CI. This may additionally indicate the clinical
value of CI for controlling ventricular rate.
Symptoms such as heart palpitation can have
a negative influence on the quality of life in AF pa-
tients. Arrhythmia worsens quality of life in 2/3 of
AF patients [39, 40]. According to Jung’s and Lu-
deritz’s published data, the most frequently report-
ed symptom is “heart palpitation” [40]. This is near-
ly always correlated with tachy AF episodes. In our
study heart palpitations were reported by patients
with tachy AF episodes as well as those with sig-
nificant irregularity. In the majority of patients
(90%) with these symptoms a high CI of > 0.2 was
found. This suggests that CI is a very important
factor, which can influence and lead to deteriora-
tion in the quality of life of AF patients. It is impor-
tant to underline that the pharmacological treatment
of patients with AF is able to reduce tachy AF epi-
sodes but not ventricular irregularity [41].
Only 10 of 42 patients with mean heart rate
< 90/min (an accepted criterion for rate control) did
not have tachy AF episodes or significant heart rate
irregularity. This is clear evidence that  mHR alone
is unable to ensure correct ventricular rate control.
This is one of the first published studies to
show that mHR is not sufficient for the management
of patients with AF. It would appear to be essential
to examine other parameters and CI may be one of
the most important in controlling ventricular rate
and preventing tachycardiomyopathy.
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Limitations of the study
Only patients with brady-tachy AF and an im-
planted pacemaker were included in the study. It is
open to question whether the same results would
be obtained in AF patients without indications for
pacemaker implantation. However the mean per-
centage of ventricular pacing (< 5%) during the VVI
40 bpm mode, should not influence our results.
Conclusions
1. Mean heart rate derived from Holter monitor-
ing is insufficient as a parameter for control-
ling ventricular rate in the majority of patients
with brady-tachy atrial fibrillation.
2. It seems that tachy atrial fibrillation episodes,
rhythm irregularity and patient symptoms, and
not only mean heart rate, are necessary for the
correct control of heart rate in patients with
atrial fibrillation.
3 The coefficient of irregularity in patients with
a correct mean heart rate may be superior to
other parameters for the assessment of rhythm
control in patients with atrial fibrillation.
References
1. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence,
incidence, prognosis and predisposing conditions for
atrial fibrillation: population-based estimates. Am
J Cardiol, 1998; 82 (1 Suppl): N2–N9.
2. Epstein AE. Strategies for rate control. In: Kowey P.,
Naccarelli GV ed. Atrial fibrillation. Marcel Dekker
& Company, New York 2005; 121–134
3. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or
rate control in atrial fibrillation — Pharmacological
Intervention in Atrial Fibrillation (PIAF): a ran-
domised trial. Lancet 2000; 356: 1789–1794.
4. Carlsson J. Mortality and stroke rates in trial of
rhythm control versus rate control in atrial fibrilla-
tion: results from the STAF pilot phase (Strategies
of Treatment of Atrial Fibrillation). Am Coll Cardiol
2001; 38: 603.
5. Galder IC, Hagens VE, Bosker HA et al. For the
Rate Control versus Electrical Cardioversion for Per-
sistent Atrial Fibrillation Study Group. A compari-
son of rate control and rhythm control in patients
with recurrent persistent atrial fibrillation. N Engl J
Med, 2002; 347: 1834–1840.
6. The Atrial Fibrillation Follow up Investigation of
Rhythm Management (AFFIRM) investigators.
A comparison of rate control and rhythm control in
patients with atrial fibrillation. N Engl J Med, 2002;
347: 1825–1833.
7. Opolski G, Torbicki A, Kosior DA et al. Rate control
vs. rhythm control in patients with nonvalvular per-
sistent atrial fibrilation: the results of the Polish How
to Treat Chronic Atrial Fibrillation Study (HOT
CAFE). Chest, 2004; 126: 476–486.
8. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/
/ESC guidelines for management of patients with
atrial fibrillation. Circulation, 2001; 104: 2118–2150.
9. Wood MA. Ventricular rate control as an endpoint
for the treatment of atrial fibrillation. Heart Rhythm,
2004; 1: B45–B51.
10. Naccarelli GV. An update on atrial fibrillation: a re-
port from the Annual American Heart Association
Session, New Orleans, 12–15.11.2000.
11. American College of Cardiology/American Heart As-
sociation, Task Force on Practice Guidelines and the
European Society of Cardiology, Committee for Prac-
tice Guidelines and Policy Conferences: ACC/AHA/
/ESC guidelines for the management of patients with
atrial fibrillation: Executive summary. Am J Coll Car-
diol, 2001; 38: 1231–1265.
12. Schumacher B. Luderitz B. Rate issues in atrial fi-
brillation: consequences of tachycardia and therapy
for rate control. Am J Cardiol, 1998; 82 (8 Suppl A):
29N–36N.
13. Twidale N, McDonald T, Nave K, Seal A. Compari-
son of the effects  of AV nodal ablation versus AV
nodal modification in patients with congestive heart
failure and uncontrolled atrial fibrillation. Pacing Clin
Electrophysiol, 1998; 21: 641–651.
14. ACC/AHA guidelines for ambulatory electrocardiog-
raphy: Executive summary and recommendations.
Circulation, 1999; 100: 886–947.
15. Greenhut SE, Fraser J, Steinhaus B, Feld G, Hughes
W. Optimized standby rate reduces the ventricular
rate variability in pacemaker patients with atrial fi-
brillation. Pacing Clin Electrophysiol, 1996; 19:
1780–1785.
16. Grogan M, Smith HC, Gersh BJ et al. Left ventricular
dysfunction due to atrial fibrillation in patients ini-
tially believed to have idiopathic dilated cardiomyop-
athy. Am J Cardiol, 1992; 69: 1570–1573.
17. Khasnis A, Jongnarangsin K, Abela G, Veerareddy S,
Reddy V, Thakur R. Tachycardia- induced cardiomyo-
pathy: A review of literature. Pacing Clin Electro-
physiol, 2005; 28: 710–721.
18. Gassage AM, Braxton Hicks JA. On auricular fibrilla-
tion. QJM, 1913; 6: 435–440.
19. Peters KG, Kienzle MG. Severe cardiomyopathy due
to chronic rapidly conducted atrial fibrillation: com-
plete recovery after restoration of sinus rhythm. Am
J Med, 1988; 85: 242–244.
20. Grogan M, Smith HC, Gersh BJ et al. Left ventricular
dysfunction due to atrial fibrillation in patients ini-
479
Michał Chudzik et al., Mean HR and the pharmacotherapy of patients with AF
www.foliacardiologica.eu
tially believed to have idiopathic dilated cardiomyo-
pathy. Am J Cardiol, 1992; 69: 1570–1573.
21. Rodriguez LM, Smeets JL, Xie B et al. Improvement
in left ventricular function by ablation of atrioventricu-
lar nodal conduction in selected patients with lone
atrial fibrillation. Am J Cardiol, 1993; 72: 1137–1141.
22. Edner M, Caidahl K, Bergfeldt L et al. Prospective
study of left ventricular function after radiofrequency
ablation of atrioventricular junction in patients with
atrial fibrillation. Br Heart J, 1995; 74: 261–267.
23. Byrne MJ, Raman JS, Alferness CA, Esler MD,
Kaye DM, Power JM. An ovine model of tachycar-
dia-induced degenerative dilated cardiomyopathy and
heart failure with prolonged onset. J Card Fail, 2002;
8: 108–115.
24. Tomita M, Ikeguchi S, Kagawa K et al. Serial his-
topathologic myocardial findings in patients with ec-
topic atrial tachycardia-induced cardiomyopathy.
J Cardiol, 1997; 29: 37–42.
25. Spinale FG, Holzgrefe HH, Mukherjee R, Arthur SR,
Child MJ, Powell JR. LV and myocyte structure and
function after early recovery from tachycardia-induced
cardiomyopathy. Am J Physiol, 1995; 268 (2 Pt 2):
H836–H847.
26. Chudzik M, Wranicz JK, Cygankiewicz I, Goch JH,
Kargul W. Pacemaker memory data compared to
twenty four hour Holter monitoring in patients with
VVI pacemaker and chronic atrial fibrillation. ANE,
2005; 10: 348–355.
27. Clark DM, Plumb VJ, Kay GN. The hemodynamics
of atrial fibrillation: the independent effect of an irregu-
lar RR interval. Circulation, 1995; 92: I-141 (abstract).
28. Clark DM, Plumb VJ, Kay GN et al. Hemodynamic
effects of an irregular sequence of ventricular cycle
lengths during atrial fibrillation. J Am Coll Cardiol,
1997; 30: 1039–1045.
29. Naito M, David D, Michelson EL. The hemodynamic
consequence of cardiac arrhythmias: evaluation of
the relative roles of abnormal atrioventricular se-
quencing, irregularity of ventricular rhythm and atri-
al fibrillation in a canine model. Am Heart J, 1983;
106: 284–291.
30. Ueshima K, Myers J, Ribis PM et al. Exercise capa-
city and prognosis in patients with chronic atrial fibril-
lation. Cardiology, 1995; 86: 108–113.
31. Daoud EG, Weiss R, Bahu M. Effect of an irregular
ventricular rhythm on cardiac output. Am J Cardiol,
1996; 78: 1433–1436.
32. Natale A, Zimerman L, Tomassoni G. Impact on ven-
tricular function and quality of life of transcatheter
ablation of atrioventricular junction in chronic fibril-
lation with a normal ventricular response. Am J Car-
diol, 1996; 78: 1431–1433.
33. Van Gelder IC, Crijns GM, Blanksma PK. Time
course of hemodynamic changes and improvement
of exercise tolerance after cardioversion of chronic
atrial fibrillation unassociated with cardiac valve dis-
ease. Am J Cardiol, 1993; 72: 560–566.
34. Ueng KC, Tsai TP, Tsai CF et al. Acute and long-
-term effects of atrioventricular junction ablation and
VVIR pacemaker in symptomatic patients with chronic
lone atrial fibrillation and normal ventricular response.
J Cardiovasc Electrophysiol, 2001; 12: 303–309.
35. Giani P, Giudici V, Leoni G. Heamodynamics of
a regular  and an irregular rhythm in atrial fibrillation.
In: Santini M. ed. Progress in clinical pacing. 1998;
Futura Media Services, Inc Armonk, NY 1998; 51–56.
36. Ellenbogen KA, Thames MD, Mohanty PK. New in-
sights into pacemaker syndrome gained from hemo-
dynamic, humoral and vascular responses during
ventricular pacing. Am J Cardiol, 1990; 65: 53–59.
37. Herbert WH. Cardiac output and the varying RR in-
terval of atrial fibrillation. J Electrocardiol, 1973; 6:
131–135.
38. Lau CP, Jiang ZY, Tang MO. Efficacy of ventricular
rate stabilization by right ventricular pacing during
atrial fibrillation. Pacing Clin Electrophysiol, 1998;
21: 542–548.
39. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG,
Pritchett ELC. Quality of life assessment in patients
with paroxysmal atrial fibrillation or paroxysmal su-
praventricular tachycardia. Am J Cardiol, 1994; 74:
826–829.
40. Jung W, Luderitz B. Quality of life in patients with
atrial fibrillation. J Cardiovasc Electrophysiol, 1998; 9
(Suppl): 177–186.
41. Chudzik M, Wranicz JK, Goch JH, Kargul W. Wpływ
stałej elektrostymulacji serca na stabilizację rytmu
u pacjentów z utrwalonym migotaniem przed-
sionków. Folia Cardiol. 2004; 11: 169–176.
